Lv1
30 积分 2025-07-10 加入
Disproportionality Analysis of Dermatologic Adverse Events Associated with Nirogacestat: Insights from the FDA Adverse Event Reporting System (FAERS)
7小时前
待确认
Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System
24天前
已完结
Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system
1个月前
已完结
Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database
1个月前
已完结
Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023
1个月前
已完结
Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS)
1个月前
已完结
Reported Psychiatric Adverse Events Among Isotretinoin Users: Monitoring Priorities from a 20-Year FAERS Database Study
1个月前
已完结
Exploring Suicidal and Self-injurious Behaviors (SSIBs) Signal Strength of Biologics in Treating Psoriasis or Psoriatic Arthritis: A 10-year Real-world Pharmacovigilance Analysis Using FAERS Database
1个月前
已完结
Post-Marketing Safety Surveillance of Adalimumab, Secukinumab, and Infliximab in Hidradenitis Suppurativa: An Analysis of the FDA Adverse Events Reporting System (FAERS) Database
1个月前
已完结
A disproportionality analysis of thromboembolic and cardiovascular adverse event signal strength across various JAK-inhibitors based on the FAERS database
2个月前
已完结
皖公网安备34019202002308
